Stem cell therapy for diabetes and related conditions: An insight
The stem cell therapy for diabetes and related conditions pipeline analysis report includes ongoing clinical and non-clinical trends in the global stem cell therapy for diabetes and related conditions treatment. Most of the pipeline therapeutics are in early stage of development, a long-lasting and less frequent dose can impact overall diabetes market.
In 2015, the American Diabetes Association (ADA) estimated that the annual total cost of diabetic patients is $223.5 billion in the US alone. The global annual cost is estimated at $465 billion and is expected to reach $510 billion a year by 2030.
Covered in this report
The report covers the present scenario and the growth prospects of the stem cell therapy for diabetes and related conditions. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
Technavio's Stem Cell Therapy for Diabetes and Related Conditions - A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.
Key questions answered in this report
How will the market evolve during the forecast period?
What are the major parameters impacting the market?
What are the key market trends?
What are the challenges to market growth?
Who are the key companies in this market space?
You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: STEM CELL THERAPY FOR DIABETES AND RELATED CONDITIONS: AN INSIGHT
PART 04: MAJOR REGULATORY AUTHORITIES
PART 05: PIPELINE LANDSCAPE
PART 06: COMPARATIVE ANALYSIS
Mid-stage molecules (Phase II)
Early-stage molecules (Phase I/II)
Pre-clinical stage molecules
Inactive and discontinued molecules
PART 07: INDICATION ANALYSIS
PART 08: THERAPEUTIC ASSESSMENT BY THERAPY TYPE
PART 09: THERAPEUTIC ASSESSMENT BY ROA
PART 10: KEY COMPANIES
Active companies: Category and parameters
PART 11: APPENDIX
List of abbreviations
List of Exhibits
Exhibit 01: Drug approval process by US FDA
Exhibit 02: Active pipeline molecules by vendors
Exhibit 03: Pipeline landscape
Exhibit 04: Pipeline molecules by numbers
Exhibit 05: Pipeline molecules by percentage
Exhibit 06: Overview: ALLO-ASC-DFU
Exhibit 07: Clinical trials description of ALLO-ASC-DFU
Exhibit 08: Overview: MPC-300-IV
Exhibit 09: Clinical trials description of MPC-300-IV
Exhibit 10: Overview: CLBS 03
Exhibit 11: Clinical trials description of CLBS 03
Exhibit 12: Overview: PDA-002
Exhibit 13: Clinical trials description of PDA-002
Exhibit 14: Overview: PEC-Encap (VC-01)
Exhibit 15: Clinical trials description of PEC-Encap (VC-01)
Exhibit 16: Overview: PEC-Direct (VC-02)
Exhibit 17: Clinical trials description of PEC-Direct (VC-02)
Exhibit 18: Overview: NSI-566
Exhibit 19: Overview: VC-03
Exhibit 20: Overview: VC-04
Exhibit 21: Overview: MultiStem
Exhibit 22: Overview: Research Program
Exhibit 23: Overview: Diabetes beta cell therapy
Exhibit 24: Overview: Cell therapy for diabetes
Exhibit 25: Overview: Cell therapy for diabetes
Exhibit 26: Overview: Cell therapy for diabetes
Exhibit 27: Overview: ProTrans
Exhibit 28: Inactive molecules
Exhibit 29: Discontinued molecule
Exhibit 30: Analysis by indication
Exhibit 31: Overview of indications
Exhibit 32: Assessment of pipeline products by therapy
Exhibit 33: Assessment of pipeline products by RoA
Exhibit 34: Active companies: Category and parameters 2017
Exhibit 35: Segmentation of companies
Exhibit 36: Overview: Anterogen 2017
Exhibit 37: Overview: Athersys 2017
Exhibit 38: Overview: Caladrius Biosciences 2017
Exhibit 39: Overview: Cellular Therapeutics 2017
Exhibit 40: Overview: Islexa 2017
Exhibit 41: Overview: Kadimastem 2017
Exhibit 42: Overview: Mesoblast 2017
Exhibit 43: Overview: Neuralstem 2017
Exhibit 44: Overview: NextCell Pharma 2017
Exhibit 45: Overview: Novo Nordisk 2017
Exhibit 46: Overview: Orgenesis 2017
Exhibit 47: Overview: Sanofi 2017
Exhibit 48: Overview: ViaCyte 2017
Make an enquiry before buying this Report
Please fill the enquiry form below.